Treatment News : Atripla, Sustiva Component Linked to Neuron Damage

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 28, 2012

Atripla, Sustiva Component Linked to Neuron Damage

A byproduct formed during the breakdown of efavirenz—found in Sustiva and Atripla—appears to damage nerve cells, according to new Johns Hopkins University research published online ahead of print by the Journal of Pharmacology and Experimental Therapeutics and summarized in a news announcement. The scientists hypothesize, but did not conduct the studies necessary to prove, that this may contribute to cognitive impairment in people living with HIV.

Efavirenz is known to be very good at controlling the virus and is one of the few that crosses the blood-brain barrier and can target potential reservoirs of virus in the brain. It may also cause a variety of central nervous system-related side effects, such as nightmares and feeling “buzzed” during the first few weeks of treatment. Now it appears as if 8-hydroxyefavirenz, one of the metabolites created when efavirenz is metabolized by the liver, can damage important “dendritic spines” of neurons—the cells’ critical information processing points.

Is this toxicity clearly associated with, and indeed a cause of, memory declines and other neurocognitive problems in people living with HIV?  Additional research, including analyses of data involving people who have been using efavirenz compared with those who have not, will be necessary. The researchers did note, however, that "concentrations of efavirenz and [8-hydroxyefavirenz] in the cerebral spinal fluid of HIV-infected [NorthEastern AIDS Dementia study participants] taking efavirenz were within the range that damaged neurons in culture."

The Johns Hopkins researchers add that a minor modification to efavirenz’s structure may block its effects on nerve cells, without affecting the drug’s effectiveness.

To read the Journal of Pharmacology and Experimental Therapeutics report (paid subscription required), click here.
To read the Johns Hopkins news announcement, click here.

Search: atripla, sustiva, neurocognitive, neurons, dendritic spines, memory, thinking, dementia, brain, central nervous system, johns hopkins

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (31 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.